Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
大柴胡颗粒 (Dacaihu Granules) is a traditional Chinese medicine (TCM) formulation developed and manufactured by Jinghua Pharmaceutical Group Nantong. It is a modernized granule form of the classical TCM formula Da Chaihu Tang (Major Bupleurum Decoction). The formulation typically consists of several herbal ingredients, including *Bupleurum chinense* (Chaihu), *Scutellaria baicalensis* (Huangqin), *Rheum palmatum* (Dahuang), *Citrus aurantium* (Zhishi), *Pinellia ternata* (Banxia), *Paeonia lactiflora* (Baishao), *Zingiber officinale* (Shengjiang), and *Ziziphus jujuba* (Dazao). It is traditionally used to harmonize the Shao Yang and purge heat from the Yang Ming, often indicated for conditions involving both interior and exterior symptoms such as cholecystitis, pancreatitis, and digestive disorders. Jinghua Pharmaceutical has also explored its use in treating diabetes and urticaria (hives) through patent filings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 大柴胡颗粒.